Fig. 2From: Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer(A) Forest plots of the relationship between advanced lung cancer inflammation index and overall survival (heterogeneity index I2 = 57.6%, p = 0.012; HR: 0.51, 95% CI: 0.37–0.70, p < 0.001). (B) Sensitivity analysis of the association between advanced lung cancer inflammation index and overall survival. HR, hazard ratio; CL, confidence intervalBack to article page